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AbstrAct
Background Baricitinib was efficacious in a 24-week 
phase iii study in patients with rheumatoid arthritis (ra) 
and an inadequate response to conventional synthetic 
disease-modifying anti rheumatic drugs (DMarDs) 
(csDMarDs) (ra-BUilD).
Objectives to evaluate radiographic progression of 
structural joint damage in ra-BUilD patients over 48 
weeks of baricitinib treatment in the long-term extension 
study, ra-BeYOnD.
Methods in ra-BUilD, patients were randomised to 
placebo, baricitinib 2 mg or 4 mg once daily, with rescue 
possible from week 16. Patients completing ra-BUilD and 
entering ra-BeYOnD continued to receive the baricitinib 
dose received at the end of ra-BUilD. Patients receiving 
placebo were switched to baricitinib 4 mg in ra-BeYOnD. 
Joint damage was measured using the van der Heijde 
modified total Sharp score. to account for missing scores 
and scores obtained after rescue, switch or discontinuation 
of study drug, data were analysed using (1) linear 
extrapolation (le) and (2) observed/last observation carried 
forward (lOcF). the observed/lOcF method used all 
available observed data, including after rescue or switch, 
with patients analysed according to original treatment 
assignment.
Results Using le, radiographic progression at 24 
and 48 weeks was statistically significantly lower for 
both baricitinib 2 or 4 mg compared with placebo. Only 
baricitinib 4 mg demonstrated statistically significant 
inhibition of progressive radiographic joint damage 
compared with patients initially randomised to placebo 
using observed/lOcF at week 48.
Conclusions Once daily oral baricitinib inhibited 
radiographic progression of structural joint damage in 
patients with an inadequate response or intolerance to 
csDMarDs over 48 weeks. the most robust benefit was 
seen for the 4 mg dose.
InTROduCTIOn
Rheumatoid arthritis (RA) is, if untreated, 
associated with progressive joint destruction, 
significantly compromised quality of life and 
reduced survival.1 2 The progressive joint 
damage caused by RA is associated with long-
term functional disability3; therefore, a treat-
ment goal for RA is to inhibit structural joint 
damage through the use of disease-modi-
fying antirheumatic drugs (DMARDs). For a 
drug to be defined as a DMARD, it has to 
demonstrate that it is capable of inhibiting 
Key messages
What is already known about this subject?
 ► in the phase iii study ra-BUilD (Dougados et al Ann 
Rheum Dis 2017;76:88–95), baricitinib inhibited 
progression of radiographic joint damage over 24 
weeks in patients with active rheumatoid arthritis 
who had an inadequate response to conventional 
synthetic disease-modifying antirheumatic drugs 
(DMarDs).
What does this study add?
 ► this study demonstrates that treatment with 
baricitinib 2 and 4 mg maintains for up to 1 year 
the inhibition of structural joint damage originally 
seen at 24 weeks.
How might this impact on clinical practice?
 ► these data show the sustained disease-modifying 
capacity of baricitinib.
 ► the most robust benefit across measures was seen 
for the 4 mg dose.
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the rate of radiographic progression of structural joint 
damage.4 
Baricitinib is an oral, selective, inhibitor of JAK1 and 
JAK2 and has demonstrated clinical benefit, including 
reducing the rate of structural joint damage, in several 
studies in patients with RA.5–8 In the 24-week phase III 
RA-BUILD study (NCT01721057), baricitinib signifi-
cantly reduced radiographic progression of joint damage 
in patients with active RA who had an inadequate response 
to or were intolerant of previous conventional synthetic 
DMARDs (csDMARDs).8 On completion of the 24-week 
RA-BUILD study, patients could enrol in the long-term 
extension study, RA-BEYOND (NCT01885078). This 
report describes the effect of treatment with baricitinib 
2 or 4 mg over 48 weeks on radiographic progression 
of structural joint damage in patients who completed 
RA-BUILD and enrolled in RA-BEYOND.
MeTHOds
Patients
Patients who entered the RA-BUILD study were ≥18 years 
old with active RA (≥6/68 tender and ≥6/66 swollen 
joints; serum C reactive protein ≥3.6 mg/L (upper limit 
of normal 3.0 mg/L)), had an insufficient response 
(despite prior therapy) or intolerance to ≥1 csDMARDs 
and were biologic DMARD (bDMARD)-naïve. In the 
24-week RA-BUILD study, patients were randomised to 
placebo, baricitinib 2 mg or baricitinib 4 mg, stratified 
by region and presence of joint erosions (yes/no) on 
centrally read radiographs obtained at screening. Rescue 
treatment (baricitinib 4 mg) was assigned at week 16 for 
patients whose tender and swollen joint counts improved 
from baseline by <20% at both weeks 14 and 16. For more 
details on the patient population that participated in 
the RA-BUILD study, please see Dougados et al’s study.8 
Patients who completed the RA-BUILD study were 
eligible to enter the long-term extension study, RA-BE-
YOND. Rescue in RA-BUILD did not preclude enrolment 
in RA-BEYOND. Patients were not eligible for participa-
tion in RA-BEYOND if they demonstrated significant 
uncontrolled laboratory abnormalities, had a known 
hypersensitivity to baricitinib, or if they permanently 
discontinued baricitinib during the RA-BUILD study. 
Radiographs from RA-BUILD baseline, and weeks 24 and 
48 in RA-BEYOND were scored in the reading campaign 
used to generate the data for these analyses.
study protocol and oversight
RA-BEYOND is a phase III, multicentre, extension study 
evaluating the long-term efficacy and safety of baricitinib 
(2 mg once daily (QD) and 4 mg QD) in patients with RA.
Patients who completed RA-BUILD and entered 
RA-BEYOND continued to receive the dose of barici-
tinib they were receiving at the end of RA-BUILD (baric-
itinib 2 or 4 mg). Patients receiving placebo at the end 
of RA-BUILD were switched to baricitinib 4 mg on entry 
into RA-BEYOND. Although patients and investigators 
were aware that all patients would be receiving baricitinib 
in the extension study, those who had not been rescued 
remained blinded to randomised treatment assignment 
from RA-BUILD. In RA-BEYOND, patients could continue 
to receive background open-label csDMARDs, non-ste-
roidal anti-inflammatory drugs, analgesics and/or corti-
costeroids (≤10 mg of prednisone or equivalent per day) 
being received at the completion of RA-BUILD. Patients 
with a Clinical Disease Activity Index (CDAI) score >10 
at or after 3 months following enrolment into BEYOND 
could be rescued to baricitinib 4 mg. After rescue, all 
patients would receive 4 mg and remain blinded to their 
previous treatment assignment. Investigators were free to 
prescribe new csDMARDs and add or increase dosage of 
steroids, NSAIDS and/or analgesics. Baricitinib 4 mg was 
open label after rescue. Use of bDMARDs was prohibited 
in RA-BEYOND.
The RA-BEYOND study was designed by the sponsor, 
Eli Lilly and Company, an academic advisory board 
including non-Lilly authors of this manuscript, and 
Incyte Corporation. It was conducted in accordance with 
ethical principles of the Declaration of Helsinki and 
Good Clinical Practice guidelines and approved by the 
institutional review board or ethics committee for each 
centre. All patients provided written informed consent 
before the first study procedure. The study commenced 
in June 2013 and was ongoing at the time the present 
manuscript was prepared. Lilly or its representatives 
provided data, laboratory and site-monitoring services. 
All authors participated in data analysis and interpreta-
tion, reviewed drafts and final manuscript, and provided 
critical comments. The authors vouch for the veracity 
and completeness of the data and data analyses.
efficacy
Radiographic joint damage was measured using the van 
der Heijde modified Total Sharp Score (mTSS).9 10 This 
methodology quantifies the extent of bone erosions and 
joint space narrowing for 44 and 42 joints, respectively, 
within the hands and feet with higher scores representing 
greater damage. Radiographs were scored by two primary 
readers separately and independently, blinded to chron-
ological order, patient identity and treatment group. 
The mean score obtained between the two readers was 
used in the analyses.5 6 Radiographic progression was 
determined by the change from baseline in mTSS, bone 
erosion and joint space narrowing. Progression versus 
non-progression was defined based on change from base-
line in mTSS using thresholds of 0, 0.5 or the smallest 
detectable change (SDC). The initial radiographs taken 
at RA-BUILD baseline served as the baseline radiographs 
for comparison throughout RA-BEYOND. The time 
points presented in this manuscript were all relative to 
the RA-BUILD baseline. Radiographs were obtained at 
baseline, weeks 24 and 48. The 48-week radiographs were 
obtained during the RA-BEYOND study. If the patient 
was rescued or had an early termination visit, radiographs 
were obtained only if the most recent radiographs were 
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>12 weeks earlier. All these radiographs were analysed in 
a single reading campaign.
safety
Clinical laboratory tests, vital signs and other safety 
assessments were performed at scheduled visits. The 
occurrence and severity of all adverse events (AEs) were 
recorded.
statistical analyses
Analysis of structural progression was conducted on the 
modified intent-to-treat population using patients with 
available baseline (from RA-BUILD study) and at least 
one radiographic assessment at any time after baseline. 
Analysis of covariance (ANCOVA) was used to analyse 
radiographic progression, and a logistic regression 
model was used to analyse percentage of patients with 
no progression of structural joint damage, with baseline 
value (for ANCOVA model only), treatment, region and 
centrally confirmed presence of baseline joint erosions 
in the model. The Fisher exact test was used for categor-
ical safety data or when sample size requirements for the 
aforementioned logistic regression model were not met. 
Analyses were assessed with a significance level of 0.05 
(two-sided). The SDC in mTSS was computed from the 
variability in week 0 to 24 or to week 48 (1 year) changes 
in scores assigned by the two blinded readers.11
Patients who were rescued or discontinued in either 
RA-BUILD or RA-BEYOND, or did not enter RA-BE-
YOND, were defined thereafter as non-responders 
(non-responder imputation) for categorical clinical effi-
cacy outcomes. To account for missing mTSS and data 
obtained after rescue or treatment switch, data were 
analysed using (1) linear extrapolation (LE) and (2) 
observed/last observation carried forward (LOCF). The 
LE method used radiographic data at baseline and the 
last radiograph taken before discontinuation, rescue 
Figure 1 Patient disposition through 48 weeks in RA-BEYOND. Patients who were rescued or discontinued from the 
originator study, RA-BUILD, or who completed RA-BUILD, entered RA-BEYOND and were rescued or discontinued from 
RA-BEYOND on or before 48 weeks, were defined as non-responders or had their last observations before rescue or 
discontinuation used for analyses of subsequent time points for efficacy endpoints. *Patients on placebo at the end of the 
RA-BUILD study were switched to baricitinib 4 mg on entry to RA-BEYOND. LTE, long-term extension; QD, once daily; RA, 
rheumatoid arthritis.
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or switch to impute missing data. The observed/LOCF 
method used all available observed data, including after 
rescue or switch, with patients analysed according to 
original treatment assignment. The result obtained from 
the last obtained radiograph after baseline was used for 
subsequent timepoints. Safety observations were analysed 
by assigned treatment until the time of rescue or switch 
or completion of the treatment period. P values were not 
adjusted for multiple comparison.
ResulTs
Patients
In RA-BUILD, 684 patients were randomised, and 611 
patients completed the study; 583 patients entered 
RA-BEYOND (85% of the randomised and 95% of the 
completed patients). Baseline demographics and clinical 
characteristics were similar among treatment groups.8 
See figure 1 for the number of patients who were rescued 
and a brief description of rescue criteria. The distribu-
tion of patients included in the LE and observed/LOCF 
analyses can be seen in figure 2. Patients who remained 
on baricitinib 2 mg in RA-BUILD continued on 2 mg in 
RA-BEYOND. Patients who were rescued from baricitinib 
2 to 4 mg, or who were originally randomised to placebo 
or baricitinib 4 mg, received baricitinib 4 mg in RA-BE-
YOND.
efficacy
Using the primary LE analysis, compared with placebo, 
both doses of baricitinib inhibited progression of struc-
tural joint damage as measured by mTSS, and the subcom-
ponents of joint space narrowing and bone erosion, at 
week 24. These differences persisted when analysed using 
the observed/LOCF method (figure 3A,B). Observa-
tions at week 48 revealed a similar pattern as the primary 
LE analysis. However, at week 48, the observed/LOCF 
method of analysis demonstrated that compared with 
patients initially randomised to placebo, only baricitinib 
4 mg demonstrated statistically significantly less radi-
ographic progression (including for mTSS and bone 
erosions (figure 3C,D)). Figure 3E and F presents indi-
vidual patient data on the progression at week 48 for 
both the LE and LOCF methods in probability plots. At 
week 24, compared with placebo, a numerically larger 
proportion of patients had no progression in mTSS (ie, 
changes exceeding 0, 0.5 Sharp units or the SDC) for 
Figure 2 Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients 
who were rescued or discontinued in RA-BEYOND were defined as non-responders. Missing scores and scores obtained 
after rescue or discontinuation were analysed using both LE and observed/LOCF. *LE imputations were performed for patients 
who had non-missing values at Week 48 but had been rescued before week 48 or switched at week 24 (placebo responders). 
If a patient fit into more than one reason, the reason with the earliest date was used. **This value represents all patients with 
a missing value at week 48 including those who did not enter RA-BEYOND. LE, linear extrapolation; LOCF, last observation 
carried forward; mITT, modified intent-to-treat; mTSS, modified Total Sharp Score; n, number of mITT patients; n, number of 
patients included in the analysis (with baseline and at least one postbaseline X-ray available for analysis); QD, once daily; RA, 
rheumatoid arthritis.
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Figure 3 Inhibition of radiographic progression of structural joint damage at weeks 24 and 48. (Panels A–D) The LSM change 
from baseline in structural joint damage evaluated using mTSS, joint space narrowing and erosion score. (Panels E and F)
Change from baseline in structural joint damage evaluated using the cumulative percentile change in mTSS. *P≤0.05, **P≤0.01, 
***P≤0.001 versus  placebo. †These patients were initially randomised to placebo but switched to baricitinib 4 mg at rescue or 
at week 24 prior to entry to RA-BEYOND. LSM, least squares mean; mTSS, modified Total Sharp Score.
Table 1 Proportion of patients with no radiographic progression at week 48
N/N-obs
Week 48 (LE) Week 48 (observed/LOCF)
Placebo*
228/192
Baricitinib 2 mg
229/218
Baricitinib 4 mg
227/204
Placebo*
228/204
Baricitinib 2 mg
229/219
Baricitinib 4 mg
227/206
ΔmTSS, n (%)
  ≤0 150/192 (78.1) 175/218 (80.3) 169/204 (82.8) 151/204 (74.0) 172/219 (78.5) 169/206 (82.0)
  ≤0.5 150/192 (78.1) 183/218 (83.9) 174/204 (85.3) 166/204 (81.4) 188/219 (85.8) 179/206 (86.9)
  ≤SDC (1.7) 158/192 (82.3) 190/218 (87.2) 183/204 (89.7)† 174/204 (85.3) 197/219 (90.0) 190/206 (92.2)†
The response status is dichotomised from the change in mTSS that is imputed using LE or LOCF. Comparisons  analysed  using logistic 
regression model.
*These patients were initially randomised to placebo, but switched to baricitinib 4 mg at rescue or at week 24 prior to entry to RA-BEYOND.
†P ≤ 0.05 vs placebo. 
Δ, change from baseline; LE, linear extrapolation; LOCF, last observation carried forward; mITT, modified intent-to-treat; mTSS , 
modified Total  Sharp Score; n, number of mITT patients; N-obs, number of patients with non-missing baseline and ≥1 non-missing 
postbaseline mTSS data included in analysis; SDC, smallest detectable change.
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both the baricitinib 2 and 4 mg groups using both LE and 
observed/LOCF analyses (online supplementary table 
S1). Compared with placebo, the difference was statisti-
cally significant only for the 4 mg dose and based on the 
SDC threshold. Observations at week 48 were consistent 
with those at week 24 (table 1).
safety
Safety results for the 24-week placebo-controlled trial 
RA-BUILD have been previously published.8 Briefly, 
during weeks 0–24, the rate of treatment-emergent 
adverse events (TEAEs), serious adverse events (SAEs) 
(including serious infections) and discontinuations were 
similar across placebo, baricitinib 2 mg and baricitinib 
4 mg groups (table 2); herpes zoster was reported in both 
baricitinib groups, but not in placebo. During weeks 0–48 
(RA-BEYOND), both baricitinib dose groups reported 8% 
discontinuations, with more TEAEs and SAEs (including 
serious infections) in the baricitinib 4 mg group.
dIsCussIOn
Treatment with baricitinib 2 or 4 mg once daily was asso-
ciated with reduced rates of structural progression, meas-
ured using mTSS, through 1 year in patients with RA who 
had an inadequate response to csDMARDs. Both 2 and 
4 mg doses of baricitinib were associated with structural 
benefit, but the 4 mg dose demonstrated more consistent 
reduction of structural progression when examined using 
both the LE and observed/LOCF analysis methods at 
both timepoints. The effect was seen for both the erosion 
and the joint space narrowing score. All radiographs, 
including baseline and week 24, were re-read as part of 
the scoring of the week 48 data. The change in mTSS 
at week 24 is consistent with the original reductions in 
structural progression reported in Dougados et al 2017.8 
Additionally, patients initially randomised to placebo 
who then switched to active treatment after 24 weeks had 
a larger increase in mTSS at the 48-week timepoint than 
patients who were initially randomised to treatment with 
baricitinib. This is consistent with previous findings that 
earlier control of disease is associated with reduced radi-
ographic progression.
Treatment with baricitinib not only reduced the rate of 
radiographic progression at week 48, but clinical efficacy 
(SDAI and HAQ-DI) was also maintained out to week 48 
(online supplementary table S2).12 No new safety signals 
appeared through week 48. Rates of SAEs (including 
infections) and TEAEs were higher in the baricitinib 
4 mg group than the baricitinib 2 mg group during weeks 
0–48, while AEs leading to discontinuation were similar 
across baricitinib groups at week 48.
These findings are consistent with those seen in other 
studies evaluating the effects of treatment with barici-
tinib on structural progression over 1 year.5 6 For a mole-
cule to be classified as a DMARD, an ability to inhibit 
the rate of radiographic progression of structural joint 
damage must be shown.4 These data provide further 
support that baricitinib is an effective DMARD for 
treating RA in csDMARD-inadequate response patients. 
Data from an open label LTE describing the long-term 
effects of tofacitinib on progression of radiographic 
structural damage were recently reported.13 Slightly 
over 1000 patients were followed for up to 48 months; 
the patients were receiving either 5 or 10 mg two times 
Table 2 AE overview
Weeks 0–24* Weeks 0–48
Placebo
(n=228)
Baricitinib
2 mg QD
(n=229)
Baricitinib
4 mg QD
(n=227)
Baricitinib
2 mg QD
(n=229)
Baricitinib
4 mg QD
(n=227)
SAEs† 11 (5) 6 (3) 12 (5) 12 (5) 24 (11)
  Serious infections‡ 4 (2) 2 (<1) 4 (2) 3 (1) 6 (3)
  Deaths 2 (<1) 0 0 0 1 (<1)
  AEs → permanent study drug discontinuation 11 (5) 12 (5) 14 (6) 18 (8) 19 (8)
TEAEs 161 (71) 154 (67) 162 (71) 172 (75) 186 (82)
  Infections 79 (35) 70 (31) 96 (42) 88 (38) 119 (52)
  Herpes zoster 0 4 (2) 3 (1) 8 (3) 5 (2)
  TB 0 0 1 (<1) 0 1 (<1)
  Malignancy‡ 0 0 1 (<1) 1 (<1) 1 (<1)
  MACE‡§ 2 (<1) 0 0 0 0
*The data for Weeks 0–24 have been replicated from Dougados et al.8 It has been reproduced in the table to provide context. Values include 
events that occurred during the study treatment period.
†SAEs are reported on the basis of conventional International Conference on Harmonisation definitions and not on the basis of the study 
protocol. (The protocol required that AEs or laboratory abnormalities leading to permanent discontinuation of study drug be designated as 
SAEs.) The data shown are numbers and percentages of patients with SAEs, up to the time of rescue.
‡Week 0–48 values for serious infections, malignancy, and MACE include the follow-up period.
§MACE was defined as cardiovascular death, myocardial infarction or stroke positively adjudicated by an independent cardiovascular 
evaluation committee.
AE, adverse event; MACE, QD, once daily; SAE, serious adverse events; TEAEs, treatment-emergent adverse events.
 o
n
 25 M
ay 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000662 on 8 M
ay 2018. Downloaded from
 
7van der Heijde D, et al. RMD Open 2018;4:e000662. doi:10.1136/rmdopen-2018-000662
Rheumatoid arthritis
per day of tofacitinib with and without background 
csDMARDs. Mean change in mTSS from entry into 
the LTE through 12 months was 0.25 for all patients. 
Although it is dangerous to compare data across trials, 
the baricitinib data reported in patients who all had an 
inadequate response to csDMARDS were similar.
This study had limitations. Patients who completed 
the RA-BUILD study were included in this analysis 
whether or not they entered the long-term extension 
study, RA-BEYOND; however, 85% of the randomised 
and 95% of the completed patients of RA-BUILD 
entered RA-BEYOND, thereby limiting the influence of 
dropouts. Data were imputed for patients who did not 
enter the extension study or those with missing radio-
graphs. The extension study was open-label in that 
all patients were aware that they were receiving baric-
itinib. However, the original treatment assignment as 
well as the actual dose of baricitinib remained blinded 
to the patient and investigator, and the readers scored 
all images blinded to all clinical information. Finally, 
the focus of the present manuscript is radiographic 
progression of joint damage from a single Phase three 
study and associated long-term extension data - limited 
conclusions can be drawn from the safety analyses, as 
evaluations from larger datasets that integrate informa-
tion across multiple studies are better suited for this 
purpose.14
In summary, these data provide evidence that the 
positive structural efficacy response in csDMARD-IR 
patients initially observed at 24 weeks was maintained 
over 48 weeks of treatment with baricitinib. The most 
robust benefit across measures of radiographic progres-
sion was seen with the 4 mg dose. Additional annual 
radiographic assessments will continue during the 
extension study to determine if these affects are main-
tained during longer term treatment.
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